AIDS 2021 Jun 9. Epub 2021 Jun 9.
Orlando Immunology Center, Orlando, FL, USA Baylor University Medical Center, Dallas, TX, USA Desert AIDS Project, Palm Springs, CA, USA Bliss Healthcare Services, Orlando, FL, USA Infectious Disease Specialists of Atlanta, Decatur, GA, USA Midway Immunology and Research Center, Fort Pierce, FL, USA ViiV Healthcare, Research Triangle Park, NC, USA GlaxoSmithKline, Brentford, UK ViiV Healthcare, Brentford, UK Stanford University, Palo Alto, CA.
Objectives: Dolutegravir/lamivudine (DTG/3TC) is indicated for treatment-naive and experienced people with HIV; however, questions remain about its utility in a test-and-treat setting because of potential transmitted resistance and baseline hepatitis B virus (HBV) co-infection. We present feasibility and efficacy of DTG/3TC in newly diagnosed individuals in a test-and-treat setting.
Design: The single-arm STAT study evaluated DTG/3TC in a US test-and-treat setting. Read More